|
Safety and efficacy of ABR-217620 in patients with advanced non-small cell lung cancer. Clinical Trials Info presented on Clinical Trials Search isn't intended to be a substitute for certified health advice, travels to or treatment by using a genuine physician. We are not physicians. Always consult your dr. on Safety and efficacy of ABR-217620 in patients with advanced non-small cell lung cancer. conditions. Clinical Trials Search.org is a site committed to listing clinical research studies in human subjects. Safety and efficacy of ABR-217620 in patients with advanced non-small cell lung cancer. Clinical research trials and Safety and efficacy of ABR-217620 in patients with advanced non-small cell lung cancer. health trials occur in hundreds of cities throughout the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectivity of new drugs. The propose of the studies / undertakings is to resolve certain human health questions. Clinical trials are a popular means for physicians, government agencies, and private sector companies to locate treatments for all sorts of conditions, including Safety and efficacy of ABR-217620 in patients with advanced non-small cell lung cancer.. Safety and efficacy of ABR-217620 in patients with advanced non-small cell lung cancer. Clinical Trials and other clinical trials permit volunteers to acquire medical treatment choices before they are available to the masses. Some times the test subjects obtain professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a Safety and efficacy of ABR-217620 in patients with advanced non-small cell lung cancer. clinical trial. Participants oftentimes recieve the most expert healthcare available for their Safety and efficacy of ABR-217620 in patients with advanced non-small cell lung cancer. condition. Hazards are a reality, however, and can include extra or frequent physician visits, health risks (potentially life-endangering), and/or the treatment being uneffective. Trials are federally governed with rigorous guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "S" Clinical Trials Conditions > Safety and efficacy of ABR-217620 in patients with advanced non-small cell lung cancer.  Safety and efficacy of ABR-217620 in patients with advanced non-small cell lung cancer.
Safety and efficacy of ABR-217620 in patients with advanced non-small cell lung cancer.
For Condition: Carcinoma, Non-Small-Cell Lung
Status: Recruiting
Sponsor(s): Active Biotech Research ,
Synopsis: The drug ABR-217620 is a combination of two proteins, one that recognizes tumor cells and one that triggers an attack on the tumor cells by activating some white blood cells belonging to the body's normal immune system. In animals, this results in an accumulation of white blood cells in the cancer that can fight the cancer. This study will test how much of the drug can be given to patients with non-small cell lung cancer without causing unacceptable side effects.
Details:
Eligibility:
Study Type: Interventional, Treatment, Non-Randomized, Open Label, Dose Comparison, Parallel Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria: - Patients with histologically or cytologically confirmed non-small cell lung cancer, which is refractory to (progressed on or following) currently available standard therapies. Patients must have received (or declined) at least one standard regimen for advanced/metastatic disease. - ECOG performance status of 0 or 1. - Adequate bone marrow function as defined by absolute neutrophil count greater than or equal to 1500/mm3, and platelets greater than or equal to 100,000/mm3, and hemoglobin greater than or equal to 10 g/dL. - Adequate renal function: creatinine less than or equal to 1.5 x upper limit of normal. - Adequate hepatic function: bilirubin less than or equal to 2 x upper limit of normal, and SGOT (S-ASAT) and SGPT (S-ALAT) less than or equal to 2.5 x upper limit of normal. - Life expectancy greater than 3 months. Exclusion Criteria: - Pregnant or breast-feeding women, or women of childbearing potential unless effective methods of contraception are used. - A serious uncontrolled medical disorder or active infection that would impair the patient's ability to receive study treatment. - History of or any concurrent malignancy, with the exception of the following malignancies, which may still be included: non-melanoma skin cancer, cervical cancer in situ, DCIS or LCIS of breast, past history of resected melanoma without clinical evidence of recurrent melanoma, past history of prostate cancer without clinical evidence of disease (includes patients receiving hormonal therapy). - History of brain metastases, unless stable for more than 4 weeks, and not requiring steroid therapy and without clinical symptoms of brain metastases. - Acute illness or evidence of infection, including unexplained fever (temperature greater than 100.5 degrees Fahrenheit or 38.1 degrees Celsius). - Significant symptomatic cardiac disease including: history (within the past 6 months) or current unstable angina, congestive heart failure, or myocardial infarction; or patients with uncontrolled hypertension, or hypertension that is controlled only with multiply drugs (control by monotherapy is permitted). - History of or current arrhythmias requiring treatment, with the exception of non-specific, asymptomatic ST-T wave changes or extrasystoles. - History of cerebrovascular accident within the past 5 years. - Seizure disorder requiring therapy. - Treatment with beta-blockers, including topical therapy for glaucoma, during the 6-day treatment period (5 days' treatment + 1 day in patient follow-up), and within five days prior to start of treatment. - Simultaneous participation in any other study involving investigational drugs or having participated in a study less than 4 weeks prior to start of study treatment. - Treatment with systemic or inhaled corticosteroids within 2 weeks prior to the start of treatment. - Treatment with anticoagulants, except when used to maintain the patency of a central venous line. - Active autoimmune disease requiring therapy or any history of systemic lupus erythematosus or rheumatoid arthritis. - Chemo/radio/immunotherapy less than 4 weeks (6 weeks for mitomycin C and nitrosoureas) before start of treatment. - Major surgery less than 3 weeks. - Known positive serology for HIV (patients with a known history of HIV will be excluded because of potential for unforeseen toxicity and morbidity in the immunocompromised host). - Known chronic Hepatitis B or C. - Previous exposure to murine monoclonal antibody (with HAMA titer above detection limit at baseline) or known hypersensitivity to murine proteins. - Patients currently on renal dialysis treatment
Total Enrollment:
Location and Contact Information:
Overall Study Official:
SuzanneKilany, Study Director, Active Biotech Research
Det Norske Radiumhospitalet *Recruiting*
Oslo, ,
Norway
Recruiting Paal Brunsvig +47 22 93 40 00
Fox Chase Cancer Center *Recruiting*
Philadelphia, Pennsylvania, 19111
United States
Recruiting Roger Cohen 215-729-4300
Additional Information:
Study ID Numbers: 01762001;
Study Start Date: April 2003
Record last reviewed: May 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00056537
Other Carcinoma, Non-Small-Cell Lung Studies:
1. Non-small cell lung cancer refractory to platinum-based therapy
2. Study of an oral tyrosine kinase inhibitor of VEGFR-2 for the treatment of advanced stage non-small cell lung cancer
3. Study of Temozolomide in the Treatment of Brain Metastasis from Non-small-cell Lung Cancer
4. Erlotinib in Treating Patients with Advanced Non-Small Cell Lung Cancer
5. Vaccine Treatment for Advanced Non-Small Cell Lung Cancer
Related Studies:
Other Carcinoma, Non-Small-Cell Lung Clinical Trials
Other Clinical Trials
Other Oslo Clinical Trials
Safety and efficacy of ABR-217620 in patients with advanced non-small cell lung cancer.
|
|
|
|
|
|
|
|
